HRT for Women: Pellets vs Patches vs Creams
Every delivery method for menopausal hormone therapy has trade-offs. Here's the evidence on absorption, dosing precision, safety, and which patients fit each option.
Menopausal hormone therapy is highly effective for symptom relief and durable bone health, but the delivery method shapes the experience. There is no universal best answer — only the best fit for a given patient.
Transdermal patches
The patch is the most-studied modern delivery method. It provides steady serum estradiol levels, bypasses first-pass liver metabolism (reducing VTE risk relative to oral estrogen), and is easy to adjust by changing patch strength. Skin reactions are the most common complaint; adhesive failures in humid climates are a secondary issue.
Topical creams and gels
Compounded bioidentical creams (estradiol +/- progesterone) offer fine-grained dose control and are popular among women who prefer to titrate based on symptoms. The trade-off is absorption variability — skin properties, application site, and even moisturizer use change how much drug reaches circulation. Reliable absorption requires consistent application technique.
Pellets
Subcutaneous estradiol or testosterone pellets are inserted every 3–6 months. They are convenient and produce stable levels for weeks at a time. The downside is dose inflexibility: once a pellet is in, it's in. Pellets are also frequently dosed at supraphysiologic levels, which can raise estradiol or testosterone well above physiologic targets — this is a documented quality concern in the field.
Oral micronized progesterone
For any woman with an intact uterus, progesterone is required to protect the endometrium. Oral micronized progesterone (Prometrium) taken at bedtime is the standard of care; it also has mild sedating properties many women find helpful for menopausal sleep disruption.
What Valora prescribes
Our default for most women is a transdermal estradiol patch plus oral micronized progesterone. We use creams selectively for patients who want titration flexibility. We avoid pellets except in narrow cases because the dose-control trade-off is rarely worth it.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.NAMS 2022 Hormone Therapy Position Statement Advisory Panel. Menopause. 2022;29:767-794.— The Menopause Society, 2022.
- 2.ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123:202-216.— American College of Obstetricians and Gynecologists, 2014.
- 3.Pinkerton JV. Hormone Therapy for Postmenopausal Women. N Engl J Med. 2020;382:446-455.— New England Journal of Medicine, 2020.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
